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Summary
Background: Melatonin is an endocrine hormone se-
creted by the pineal gland during night hours that pro-
vides several biological functions in the circadian rhythm 
of humans. Due to anti-estrogenic properties, melatonin 
is considered to exhibit a protective role against the de-
velopment of breast cancer (BC). Moreover, disruption of 
melatonin production through environmental influences, 
such as night work, is assumed to be a risk factor for BC. 
Materials and Methods: We reviewed recent findings 
concerning biological effects of melatonin on BC and 
conducted a meta-analysis to evaluate the association 
between melatonin and BC incidence. In random and 
fixed effects statistical models, concentrations (tertiles, 
quartiles) of the primary urinary metabolite of mela-
tonin, 6-sulfatoxymelatonin (aMT6s), were tested for the 
assumption that women with the highest values would 
exhibit a lower risk of BC. Results: Statistical analysis of 
data from 5 prospective case-control studies indicates an 
inverse association between BC risk and the highest lev-
els of urinary aMT6s. This effect seems to be influenced 
by lag intervals between aMT6s collection and the occur-
rence of BC, timing and methods of urine sampling, as 
well as genetic and environmental factors. Conclusion: 
On the basis of the results of our meta-analysis, mela-
tonin is likely to affect BC occurrence in women. How-
ever, methodological dissonances may require further 
studies.
Introduction
Melatonin (N-acetyl-5-methoxytryptamine), an endocrine 
hormone that is secreted primarily by the pineal gland during 
night hours, provides several biological functions in the circa-
dian rhythm of humans. In 1978, Cohen et al. [1] proposed the 
hypothesis that a reduced function of the pineal gland and 
thus a concomitant decrease in melatonin levels might pro-
mote the development of breast cancer (BC) in humans. 
Later, Tamarkin et al. [2] and Bartsch et al. [3] found an in-
verse relationship between nocturnal plasma melatonin peak 
concentrations in women, according to Tamarkin et al. [2] 
particularly in those with estrogen receptor (ER)-positive BC. 
Several studies also described lower rates of BC occurrence in 
blind women, thereby indicating a causative relationship be-
tween lower BC rates and an unaffected melatonin secretion 
[4–6]. Meanwhile, melatonin was demonstrated to modulate 
the estrogen-signaling pathway in hormone-dependent mam-
mary tumors and to downregulate gonadal estrogen synthesis 
[7]. Melatonin acts as a selective estrogen receptor modulator 
(SERM) and prevents estrogen-induced effects by disrupting 
the binding of the estrogen-ERa-calmodulin complex to the 
ER-binding element on DNA, thereby inhibiting estrogen- 
related transcription [8, 9]. Physiological concentrations of 
melatonin also decrease aromatase expression in MCF-7 
human BC cell lines, and promote a synergistic anti-prolifera-
tive effect with tamoxifen in anti-tumoral endocrine therapy 
[10, 11]. Probably unaffected by expression of melatonin MT1 
receptors on BC cells, administration of melatonin at physio-
logical concentrations also abrogates extragonadal steroid 
production via aromatases [12, 13]. Several animal models 
demonstrated that melatonin administration significantly re-
duces the occurrence of mammary tumors [10], in relation to 
which a physiological circadian synchronization seems to be 
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33]. Here we provide an overview of the recent findings con-
cerning the biology and impact of melatonin in relation to BC 
occurrence. A meta-analysis was conducted to quantitatively 
assess a possible association between melatonin and BC inci-
dence based on studies of urinary melatonin concentrations. 
Materials and Methods
Melatonin is metabolized in the liver and exhibits a short half-life of 
about 40 min [34]. The main degradation pathway consists of 6-hydroxy-
lation followed by conjugation for renal elimination. The concentration of 
the primary urinary metabolite of melatonin, 6-sulfatoxymelatonin 
(aMT6s) reflects the amount of nocturnal plasma melatonin in the body 
[35]. Quantitative assessment of aMT6s in urine is deemed a practical 
method to determine the circadian phase since it represents the amount 
of endogenous melatonin during collection time and is thus considered a 
reliable approximation of melatonin production in an individual, even if 
urine is stored over prolonged periods of time [36]. Although small phase 
changes could be monitored by frequent sampling of blood or saliva [37], 
simple morning urine aMT6s measurement does not interfere with the 
participant’s sleeping pattern. Despite a large variability in melatonin am-
plitudes, their range remains relatively stable within the same person [38], 
justifying singular melatonin measurements as is conducted in most re-
cent studies. For our meta-analysis based on urinary melatonin concen-
trations, 2 sampling techniques were applied: first morning urine and 24-h 
urine collection. Studies that focused on aspects such as duration of sleep 
and tumor size were excluded in the numerical analysis. The data source 
for the meta-analysis was provided by the electronic database PubMed, 
and our review comprises only English articles from 1989 to 2013. Search 
terms included melatonin, breast cancer, and urinary sulfatoxymelatonin 
(aMT6s). 
Statistical Considerations and Results
A total of 24 search results were found of which 10 studies 
measured the urinary aMT6s concentration as a surrogate of 
circulating melatonin levels: Skene et al. (1990) [39], Bartsch 
et al. (1997) [40], Travis et al. (2004) [41], Schernhammer et 
al. (2005) [42], Wu et al. (2008) [31], Schernhammer et al. 
(2008) [43], Schernhammer et al. (2009) [44], Schernhammer 
et al. (2010) [45], Davis et al. (2012) [46], and Wu et al. (2013) 
[47]. Of these 10 studies, 5 displayed their data in a similar 
manner and met the criteria of this meta-analysis (table 1). 
superior to single daily exogenous melatonin application in 
terms of disease progression [14, 15]. Melatonin was also 
found to protect animals from adriamycin-induced cardio-
toxicity, while co-administration of both substances seems to 
enhance cytotoxic effects, thereby allowing for dose reduc-
tions and attenuation of undesirable side effects [16]. How-
ever, a variety of receptor-independent anti-carcinogenic 
 effects of melatonin, such as free radical scavenging via anti-
oxidant properties and modulation of immune functions [17], 
might exist as well that render the drug potentially useful in 
the treatment of other diseases. 
In 2007, the WHO International Agency for Research on 
Cancer (IARC) classified ‘shift work that involves circadian 
disruption as probably carcinogenic to humans’ [18]. While 
several studies on mammalian animal models confirmed carci-
nogenicity of light during the biological night, evidence in 
 humans appears fragmentary [19, 20]. However, an increased 
risk for BC has been observed among women who worked 
periods of rotating night shifts [21], although this effect seems 
to be related to a high quantity of night shifts and the cumula-
tive number of years (> 6 years) a person has worked nights, 
and in particular depends on whether a night worker is a 
morning chronotype [22]. In contrast, a recent study [23] 
 associated an increasing incidence of BC with small numbers 
of night shifts per week, indicating a potential relationship to 
more frequent disruptions of the circadian rhythm with de-
ranged adaption to changes between day and night schedules 
[24]. In young women, a night shift-associated BC risk might 
even exist before the first full-term pregnancy since the mam-
mary gland is not fully differentiated until first childbirth and 
lactation [25]. 
Whether relative concentrations or the absolute decrease 
of melatonin levels with increasing years of sleep disturbance 
as well as sleep duration might affect the risk of BC remains 
inconclusive [26–31], since many studies do not provide quan-
titative urinary or serum melatonin concentrations. Independ-
ent of melatonin dynamics, interpretation of studies might be 
complicated by the expression of circadian clock genes, such 
as cell cycle regulators p53 and c-myc, which directly affect 
apoptosis and proliferation, as well as potential differences in 
culture, diet, immune reactivity, and genetic variations [32, 
Table 1. Overview of the studies used for the present meta-analysis
First author [ref.] Year Data Urine sample Menopausal status Country or cohort and time period of enrollment
Travis [41] 2004 tertiles 24-h urine pre- and 
postmenopausal
Island of Guernsey (British crown dependency), Guernsey III 
Study; 1977–1985
Schernhammer [42] 2005 quartiles first morning 
urine
primarily 
premenopausal
USA, Nurses’ Health Study II (NHSII) cohort (1989); 1996–1999 
(urine collection)
Schernhammer [43] 2008 quartiles 12-h overnight 
urine
postmenopausal Italy, Hormones and Diet in the Etiology of Breast Cancer Risk 
cohort (ORDET cohort, postmenopausal); 1987–1992
Schernhammer [44] 2009 quartiles first morning 
urine
postmenopausal USA, Nurses’ Health Study (NHS) cohort (1976); 2000–2002 
(urine collection)
Schernhammer [45] 2010 quartiles 12-h overnight 
urine
premenopausal Italy, Hormones and Diet in the Etiology of Breast Cancer Risk 
cohort (ORDET cohort, premenopausal); 1987–1992
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To evaluate a potential publication bias, a funnel plot was 
constructed. The linear regression test of funnel plot asymme-
try was performed and suggests that the data is distributed 
evenly and there is no indication of a selection bias (p = 0.94). 
Although the number of studies seems too small to exclude 
selection bias, the p value and funnel plot (figures not shown) 
do not indicate evidence thereof. 
Conclusions drawn from these 5 evaluable studies can be 
summarized in brief as follows: Travis et al. [41] found no 
 significant difference in urinary melatonin concentrations in 
BC patients and controls (Guernsey III study). In 2005 
(NHSII) and 2008 (ORDET cohort), Schernhammer et al. 
[42, 43] reported that increased melatonin levels were statisti-
cally significantly associated with lower risk of invasive BC in 
pre- and postmenopausal women. This inverse association 
was again confirmed by Schernhammer et al. in 2009 (NHS) 
[44], while in 2010, Schernhammer et al. also reported a posi-
tive association between aMT6s concentration and BC risk in 
premenopausal women (ORDET cohort) [45]. In particular, 
when cases were excluded which exhibited a lag time below 
2 years between urine collection and BC diagnosis, melatonin 
had a protective effect on premenopausal BC, i.e. an inverse 
association could be observed [45]. Since most samples from 
the recent study by Wu et al. [47] were not derived from 
first morning voids but from randomly timed spot urine, 
 unfortunately, this study was deemed not suitable for our 
meta-analysis. 
Upon statistical considerations concerning these studies, 
melatonin concentrations were classified into quartiles or 
 tertiles according to the one-time overnight urinary aMT6s 
concentration (table 2). Since our assumption was that women 
in the highest quartile (exhibiting the highest melatonin 
 values) would experience a lower risk of developing BC com-
pared to women in the lowest quartile (i.e. exhibiting a risk 
ratio smaller than 1), the relative BC risks of the highest and 
lowest quartile (tertile respectively) were determined, com-
pared, and used to calculate the corresponding odds ratios. 
An important factor, which was taken into account, is the 
lag time between urine sample collection and diagnosis of BC. 
Since the presence of a preclinical tumor might have influ-
enced the basic melatonin level, 2 studies [41, 45] excluded 
individuals in which cancer diagnosis occurred within less 
than 2 years of urine collection (data not shown). However, 
Travis et al. [41] reported unchanged results when an adjust-
ment for a 2-year lag time was performed. In the 2008 study 
by Schernhammer et al. [43], the mean time between urine 
collection and diagnosis was 80 months (± 50 months standard 
deviation (SD)), while in Schernhammer et al. 2009 [44] this 
time interval was only 30 months (± 18 months SD).
Using the data with a 2-year lag time (where specified), led 
to the following considerations: To decide whether to use a 
fixed or random effects model in this meta-analysis, a test of 
heterogeneity (Cochran’s Q) was performed and produced a 
p value of 0.21. In meta-analyses with a fixed effect, it is as-
sumed that the same effect underlies each study and that the 
observed variability occurs only due to sample variability. 
However, with a p value (obtained from the test of homoge-
neity) higher than 0.05, the null hypothesis cannot be rejected, 
i.e. this p value indicates no evidence against homogeneity. 
Consequently, the fixed effects model could be applied. As 
mentioned above, the sample size is considered small, and 
hence the Cochran’s Q test has low power. In addition to sam-
ple variability, however, analysis may also be performed on 
the assumption that the underlying effect between the studies 
varies randomly [48]. Using the random and fixed effects 
models, a relative risk of 0.82 was obtained. Statistical signifi-
cance is attained in the random as well as in the fixed effects 
model: 95% confidence interval (0.68; 0.99), p value 0.04 for 
the random effects model, and 95% confidence interval (0.71; 
0.95), p value 0.01 for the fixed effects model. Although not 
Table 2. Data used for urinary melatonin meta-analysis (Event 1 = cases in the highest quartile, Event 2 = cases in the lowest quartile, n = total of 
respective quartile; case subjects defined as women who developed breast cancer after their enrollment in the study cohort; matched control subjects 
were randomly chosen, alive, and free of cancer at the time of diagnosis of the index case subject)
First author [ref.] Year Event 1 n 1 Event 2 n 2 Comment
Travis [41] 2004 46 163 39 158 tertiles, 24-h urine, pre- and postmenopausal
Schernhammer [42] 2005 23 96 50 123 first morning urine, primarily premenopausal
Schernhammer [43] 2008 40 218 56 233 12-h overnight urine, postmenopausal
Schernhammer [44] 2009 75 210 107 243 first spot morning urine, postmenopausal
Schernhammer [45] 2010 30 113 28 93 12-h overnight urine, premenopausal
Fig. 1. Forest plot illustrating the combined 
estimated risk ratio for breast cancer from  
the meta-analysis.
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with a favorable prognosis, i.e. ER-positive and node-negative 
tumors [55–57], although this trend was no longer seen in 
older and postmenopausal women in whom circulating aMT6s 
levels seem to decline [39]. In contrast, low aMT6s excretion 
was reported with increasing tumor size, and the melatonin 
amplitude normalized again after tumor removal [3, 40]. 
So far, available studies provide only little information on 
how to determine which collection time would optimally re-
flect biological effects of melatonin. Although urinary aMT6s 
is deemed an appropriate metabolite associated with non-in-
vasive collection procedures, it only represents a surrogate for 
endogenous periodical melatonin secretion. Since studies 
measured aMT6s concentrations e.g. over 24 h, 12 h, or in the 
first morning urine as well as randomly timed spot urine, that 
information cannot reliably be combined for calculations. 
Moreover, 24-h urinary melatonin assessment may reflect the 
nocturnal increase in melatonin concentrations, but does not 
consider peak and minimum values. Wu et al. [47] therefore 
suggested that randomly timed spot urine samples are not 
suitable as a surrogate for melatonin concentrations in hu-
mans and even provide an inaccurate comparison for women 
in the same cohort. Since it remains unclear to what extent a 
preclinical breast tumor might influence melatonin concentra-
tions, supplemental information on lag times seems manda-
tory [39, 41, 47].
Thus, further investigations need to evaluate methods of 
melatonin assessment in order to facilitate the comparison of 
different studies and ethnic groups with a focus on longitudi-
nal analysis and dynamics of melatonin secretion in individu-
als before tumor discovery and under treatment. Finally, clini-
cal trials designed to exogenously administer melatonin may 
be able to confirm effects of melatonin on BC incidence and 
provide information on dosage and long-term safety. For this, 
appropriate (range between the 75th and 100th percentile) 
levels of urinary aMT6s could be achieved e.g. by administra-
tion of synthetic melatonergic agonists with extended half-
lives [34, 58]. Alternatively, filter glasses and light systems 
that block blue spectra and short-term exposure to bright arti-
ficial light should protect shift workers from an unintended 
melatonin decline [20, 59–61]. In the light of the present trend 
towards a 24-h society, the current data on the effects of mela-
tonin may warrant further investigations with a focus also on 
cancer prevention in men [62].
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all included studies suggest an effect in the same direction, the 
confidence intervals are overlapping in all of them. The com-
bined estimated risk ratio is smaller than 1 and hence implies 
that a reduced BC risk prevails in women with higher mela-
tonin levels (fig. 1).
Discussion
We identified 5 prospective case-control studies that met 
the inclusion criteria and were finally used for statistical calcu-
lations. Although Schernhammer is co-author in 4 of the 
5 studies, their data sets can be considered different from each 
other (table 1, funnel plot). The analysis also revealed the 
 importance of a defined lag time between urine collection 
and BC diagnosis in order to appropriately assess combined 
risk evaluations for BC upon urinary melatonin excretion 
[45]. In this regard, the ORDET cohort in premenopausal 
women found highly variable odds ratios, while a significant 
BC risk reduction of 34% in the highest category of aMT6s 
levels (combined estimate 0.66) was obtained only when data 
with a lag time of > 2 years were analyzed [41, 45, 47]. In 
 contrast, adjustment for a 2-year lag time presented un-
changed results in the study by Travis et al. [41]. However, the 
studies by Travis et al. [41] and Wu et al. [47] potentially 
failed to demonstrate a protective effect of melatonin due to 
the variable timing of sample collection; both studies were 
based on measurement of non-timed urine collections (24-h 
and randomly timed spot urine). Considering the importance 
of lag-time, our meta-analysis apparently displays a trend 
 towards a protective effect of melatonin on BC occurrence, 
although only marginally significant (fig. 1).
Biological effects of melatonin might also be compromised 
by mutations in the melatonin receptors (MTNR1a and 
 MTNR1b) as well as alterations of the enzyme arylalkylamine 
N-acetyltransferase (AA-NAT) which catalyzes a key step of 
melatonin synthesis in the pineal gland, and gets rapidly 
 in activated when exposed to light at night [49, 50]. Whilst a 
 genome-wide association study from the Shanghai Breast 
Cancer Study discovered single nucleotide polymorphisms 
concerning the melatonin receptor expression, an association 
with variable susceptibility to BC may correspond to different 
phenotypes within a population of the same racial origin [51]. 
Consequently, results and dynamics of melatonin concentra-
tion from Chinese cohorts [47] need to be interpreted with 
 respect to epigenetic modifications, menopausal status, and 
dietary as well as environmental variables such as sleep depri-
vation and compromised immune function [52–54]. 
While most studies and our meta-analysis evaluated mela-
tonin levels before BC occurrence, assessments of melatonin 
levels in patients with manifest cancer indicate that the tu-
mors themselves might affect melatonin secretion upon sys-
temic endocrine reactivity towards cancer. Higher melatonin 
levels seemed prevalent in untreated BC patients and those 
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